Risk-adjusted chemoradiation according to human papilloma viral status for anal cancer: a pilot study.
IMRT
anal cancer
chemoradiation
human papilloma virus
risk-adjusted therapy
Journal
Frontiers in oncology
ISSN: 2234-943X
Titre abrégé: Front Oncol
Pays: Switzerland
ID NLM: 101568867
Informations de publication
Date de publication:
2023
2023
Historique:
received:
10
03
2023
accepted:
18
05
2023
medline:
17
7
2023
pubmed:
17
7
2023
entrez:
17
7
2023
Statut:
epublish
Résumé
HPV-associated or positive (HPV+) anal cancer patients may have better outcome compared to those with HPV negative (HPV-) disease. We report a planned interim analysis of a prospective registry study that tailors chemoradiation (CRT) for anal cancer according to HPV status. HPV+ patients received de-escalated radiation doses of 45, 50.4 and 55.8 Gy, while HPV- received 50.4, 55.8 and 63 Gy for T1, T2 and T3/T4 disease respectively. Chemotherapy consisted of a single dose of mitomycin-C and oral capecitabine on days of RT. All patients were planned by VMAT following CT, PET/CT and MR simulation. This cohort (n = 24) had a minimum 24-month follow-up. Disease free survival (DFS) and local failure rates (LFR) were compared with 180 patients managed by standard CRT (2 cycles of mitomycin-C and 5-fluorouracil, radiation doses 50.4-63 Gy based on T-category) from 2011-2018. Propensity score comparison was performed using a retrospective to prospective 2 to 1 match based on tumor size and N-category. In the HPV+ cohort (n = 20), there were 2 local failures. Two of 4 HPV- patients failed locally. The 30-month DFS and LFR were 79% and 17% respectively. Similar DFS and LFR were observed in the retrospective (80% and 15% respectively) and matched patients (76% and 16% respectively). No grade ≥3 neutropenia and febrile neutropenia were observed in the registry cohort whereas 19% and 14% respectively were seen in the retrospective patients. De-escalation of CRT for HPV+ anal cancer may result in decreased acute toxicities and similar cancer outcomes compared to standard CRT.
Sections du résumé
Background and purpose
UNASSIGNED
HPV-associated or positive (HPV+) anal cancer patients may have better outcome compared to those with HPV negative (HPV-) disease. We report a planned interim analysis of a prospective registry study that tailors chemoradiation (CRT) for anal cancer according to HPV status.
Materials and methods
UNASSIGNED
HPV+ patients received de-escalated radiation doses of 45, 50.4 and 55.8 Gy, while HPV- received 50.4, 55.8 and 63 Gy for T1, T2 and T3/T4 disease respectively. Chemotherapy consisted of a single dose of mitomycin-C and oral capecitabine on days of RT. All patients were planned by VMAT following CT, PET/CT and MR simulation. This cohort (n = 24) had a minimum 24-month follow-up. Disease free survival (DFS) and local failure rates (LFR) were compared with 180 patients managed by standard CRT (2 cycles of mitomycin-C and 5-fluorouracil, radiation doses 50.4-63 Gy based on T-category) from 2011-2018. Propensity score comparison was performed using a retrospective to prospective 2 to 1 match based on tumor size and N-category.
Results
UNASSIGNED
In the HPV+ cohort (n = 20), there were 2 local failures. Two of 4 HPV- patients failed locally. The 30-month DFS and LFR were 79% and 17% respectively. Similar DFS and LFR were observed in the retrospective (80% and 15% respectively) and matched patients (76% and 16% respectively). No grade ≥3 neutropenia and febrile neutropenia were observed in the registry cohort whereas 19% and 14% respectively were seen in the retrospective patients.
Conclusion
UNASSIGNED
De-escalation of CRT for HPV+ anal cancer may result in decreased acute toxicities and similar cancer outcomes compared to standard CRT.
Identifiants
pubmed: 37456246
doi: 10.3389/fonc.2023.1183854
pmc: PMC10346840
doi:
Types de publication
Journal Article
Langues
eng
Pagination
1183854Informations de copyright
Copyright © 2023 Chu, Taggar, Ung, Chan, Earle, Karotki, Pasetka, Presutti, Wong, Zhang and Wong.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
J Clin Oncol. 2006 Dec 20;24(36):5630-6
pubmed: 17179101
J Clin Oncol. 2012 Jun 1;30(16):1941-8
pubmed: 22529257
Int J Radiat Oncol Biol Phys. 2009 Jul 1;74(3):824-30
pubmed: 19117696
Radiother Oncol. 2015 Feb;114(2):257-63
pubmed: 25497872
Semin Radiat Oncol. 2021 Oct;31(4):349-360
pubmed: 34455990
Oncotarget. 2018 Apr 17;9(29):20439-20450
pubmed: 29755663
JAMA. 2008 Apr 23;299(16):1914-21
pubmed: 18430910
J Clin Oncol. 2012 Dec 10;30(35):4344-51
pubmed: 23150707
Br J Cancer. 2010 Mar 30;102(7):1123-8
pubmed: 20354531
Colorectal Dis. 2019 Apr;21(4):387-391
pubmed: 30687991
Eur J Cancer. 2021 Nov;157:165-178
pubmed: 34517306
Surg Oncol Clin N Am. 2017 Jan;26(1):73-90
pubmed: 27889038
Oncotarget. 2017 Dec 21;9(8):8081-8088
pubmed: 29487716
Lancet Oncol. 2013 May;14(6):516-24
pubmed: 23578724
Lancet. 1996 Oct 19;348(9034):1049-54
pubmed: 8874455
Cancer Treat Res Commun. 2021;26:100287
pubmed: 33360327
J Clin Oncol. 1996 Sep;14(9):2527-39
pubmed: 8823332
Radiother Oncol. 2018 Feb;126(2):222-228
pubmed: 29217122
Dis Colon Rectum. 1981 Mar-Apr;24(2):73-5
pubmed: 7215078